180 related articles for article (PubMed ID: 9241008)
1. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.
Alderman J; Preskorn SH; Greenblatt DJ; Harrison W; Penenberg D; Allison J; Chung M
J Clin Psychopharmacol; 1997 Aug; 17(4):284-91. PubMed ID: 9241008
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine.
Preskorn SH; Alderman J; Chung M; Harrison W; Messig M; Harris S
J Clin Psychopharmacol; 1994 Apr; 14(2):90-8. PubMed ID: 8195463
[TBL] [Abstract][Full Text] [Related]
3. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
4. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
[TBL] [Abstract][Full Text] [Related]
5. The effect of sertraline on the pharmacokinetics of desipramine and imipramine.
Kurtz DL; Bergstrom RF; Goldberg MJ; Cerimele BJ
Clin Pharmacol Ther; 1997 Aug; 62(2):145-56. PubMed ID: 9284850
[TBL] [Abstract][Full Text] [Related]
6. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
Ereshefsky L; Riesenman C; Lam YW
Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of the newer antidepressants.
Burke MJ; Harvey AT; Preskorn SH
Am J Med; 1996 Jan; 100(1):119-21. PubMed ID: 8579077
[No Abstract] [Full Text] [Related]
8. Managing rapid metabolizers of antidepressants.
Kraus RP; Diaz P; McEachran A
Depress Anxiety; 1996-1997; 4(6):320-7. PubMed ID: 9166660
[TBL] [Abstract][Full Text] [Related]
9. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline.
Preskorn S
Int Clin Psychopharmacol; 1994 Jun; 9 Suppl 3():13-9. PubMed ID: 7963446
[TBL] [Abstract][Full Text] [Related]
10. Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
Laine K; De Bruyn S; Björklund H; Rouru J; Hänninen J; Scheinin H; Anttila M
Eur J Clin Pharmacol; 2004 Feb; 59(12):893-8. PubMed ID: 14730412
[TBL] [Abstract][Full Text] [Related]
11. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults.
Nichols AI; Fatato P; Shenouda M; Paul J; Isler JA; Pedersen RD; Jiang Q; Ahmed S; Patroneva A
J Clin Pharmacol; 2009 Feb; 49(2):219-28. PubMed ID: 19001559
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline.
Alfaro CL; Lam YW; Simpson J; Ereshefsky L
J Clin Psychopharmacol; 1999 Apr; 19(2):155-63. PubMed ID: 10211917
[TBL] [Abstract][Full Text] [Related]
13. Drug-drug interactions.
Preskorn SH
J Clin Psychiatry; 1996 May; 57(5):223-7. PubMed ID: 8626354
[No Abstract] [Full Text] [Related]
14. Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.
Harris RZ; Salfi M; Posvar E; Hoelscher D; Padhi D
Eur J Clin Pharmacol; 2007 Feb; 63(2):159-63. PubMed ID: 16680561
[TBL] [Abstract][Full Text] [Related]
15. Interactions between sertraline and tricyclic antidepressants.
Lydiard RB; Anton RF; Cunningham T
Am J Psychiatry; 1993 Jul; 150(7):1125-6. PubMed ID: 8317590
[No Abstract] [Full Text] [Related]
16. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
[TBL] [Abstract][Full Text] [Related]
17. Coadministration of nefazodone and desipramine: a pharmacokinetic interaction study.
Khan AY; Preskorn SH; Horst WD
J Pak Med Assoc; 2007 May; 57(5):230-5. PubMed ID: 17571477
[TBL] [Abstract][Full Text] [Related]
18. Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults.
Nichols AI; Abell M; Chen Y; Behrle JA; Frick G; Paul J
Int Clin Psychopharmacol; 2013 Mar; 28(2):99-105. PubMed ID: 23221858
[TBL] [Abstract][Full Text] [Related]
19. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects.
Patroneva A; Connolly SM; Fatato P; Pedersen R; Jiang Q; Paul J; Guico-Pabia C; Isler JA; Burczynski ME; Nichols AI
Drug Metab Dispos; 2008 Dec; 36(12):2484-91. PubMed ID: 18809731
[TBL] [Abstract][Full Text] [Related]
20. [New antidepressive agents].
LaBranche S
Union Med Can; 1995 Nov; 124(3):8-13. PubMed ID: 8560639
[No Abstract] [Full Text] [Related]
[Next] [New Search]
